Epitalon
⊘ Insufficient evidence
Peptide Database
GHK-Cu (Copper Peptide)
A naturally-occurring tripeptide-copper complex with characterized topical effects on skin, but speculative claims when used by injection.
Cagrilintide / CagriSema
A long-acting amylin analog that, when paired with semaglutide, produces meaningfully greater weight loss than either alone.
IGF-1 LR3
A potent IGF-1 analog with documented cancer-promotion concerns when used chronically off-label for muscle growth.
Vosoritide
A C-type natriuretic peptide (CNP) analog approved for height growth in children with achondroplasia. FDA-approved 2021 (Voxzogo) and EMA-approved same year. Phase 3 trials showed…
Elamipretide
A mitochondria-targeting tetrapeptide that became the first FDA-approved mitochondrial-targeted therapeutic when it received accelerated approval as Forzinity in September 2025 for Barth syndrome — an…
Abaloparatide
A synthetic analog of parathyroid hormone-related protein (PTHrP) approved as an anabolic (bone-building) therapy for severe osteoporosis.
Icatibant
A synthetic decapeptide bradykinin B2 receptor antagonist for on-demand treatment of acute HAE attacks.
Octreotide
A synthetic somatostatin analog that has been a workhorse of endocrine and oncology practice since the 1980s.
Lutetium-177 dotatate
A peptide-receptor radionuclide therapy (PRRT) — somatostatin analog conjugated to a beta-emitting radionuclide. Marketed as Lutathera. FDA-approved 2018 based on the Phase 3 NETTER-1 trial…